An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years

Resilience Government Services, Inc.3 sites in 2 countries231 target enrollmentMay 2009

ConditionsInfluenza Avian Influenza

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Influenza
Sponsor: Resilience Government Services, Inc.
Enrollment: 231
Locations: 3
Primary Endpoint: Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the booster vaccination defined as titer measured by microneutralization test >= 1:20.
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The main objective of the study is to assess the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult population when administered according to a single prime-boost schedule.

Registry

clinicaltrials.gov

Start Date

May 2009

End Date

June 2011

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Resilience Government Services, Inc.

Eligibility Criteria

Inclusion Criteria

•Male and female subjects will be eligible for participation in this study if they:
•are 18 to 59 years of age, inclusive, on the day of screening
•have an understanding of the study and its procedures, agree to its provisions, and give written informed consent prior to study entry
•are generally healthy, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination
•are physically and mentally capable of participating in the study and follow its procedures
•agree to keep a daily record of symptoms for the duration of the study
•if female of childbearing potential: have a negative urine pregnancy test result within 24 hours prior to the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study

Exclusion Criteria

•Subjects will be excluded from participation in this study if they:
•have a history of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza vaccine
•are at high risk of contracting H5N1 influenza infection (e.g. poultry workers)
•currently have or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
•have any inherited or acquired immunodeficiency
•have a disease or are currently undergoing a form of treatment or were undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (\> 800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs
•have a history of severe allergic reactions or anaphylaxis
•have a rash, dermatological condition or tattoos which may interfere with injection site reaction rating
•have received any blood products or immunoglobulins within 90 days prior to study entry
•have donated blood or plasma within 30 days prior to study entry

Outcomes

Primary Outcomes

Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the booster vaccination defined as titer measured by microneutralization test >= 1:20.

Time Frame: 21 days

Secondary Outcomes

Number of subjects with antibody response associated with protection 21, 42, 180 and 360 days after the priming vaccination and 21 days after the booster vaccination(at the timepoints stated above)